breast cancer - HER2-positive | ||
es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | |
trastuzumab based treatment | ||
trastuzumab plus endocrine therapy | SYSUCC-002 | |
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | GeparQuinto |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -